Gazyva enhances standard care for lupus nephritis, Phase 2 trial finds
Adding Gazyva (obinutuzumab) to standard-of-care therapy for two years reduced the risk of treatment failure, diminished kidney function or death by 60% in people with lupus nephritis, a lupus complication marked by kidney inflammation and damage. The number of lupus nephritis flares, or periods of sudden worsening, also…